Centre For Pediatrics and Adolescent Medicine, University of Freiburg, Freiburg, Germany.
Am J Med Genet A. 2010 Oct;152A(10):2543-9. doi: 10.1002/ajmg.a.33641.
We recently reported on the deficiency of carbohydrate sulfotransferase 3 (CHST3; chondroitin-6-sulfotransferase) in six subjects diagnosed with recessive Larsen syndrome or humero-spinal dysostosis [Hermanns et al. (2008); Am J Hum Genet 82:1368-1374]. Since then, we have identified 17 additional families with CHST3 mutations and we report here on a series of 24 patients in 23 families. The diagnostic hypothesis prior to molecular analysis had been: Larsen syndrome (15 families), humero-spinal dysostosis (four cases), chondrodysplasia with multiple dislocations (CDMD "Megarbane type"; two cases), Desbuquois syndrome (one case), and spondylo-epiphyseal dysplasia (one case). In spite of the different diagnostic labels, the clinical features in these patients were similar and included dislocation of the knees and/or hips at birth, clubfoot, elbow joint dysplasia with subluxation and limited extension, short stature, and progressive kyphosis developing in late childhood. The most useful radiographic clues were the changes of the lumbar vertebrae. Twenty-four different CHST3 mutations were identified; 16 patients had homozygous mutations. We conclude that CHST3 deficiency presents at birth with congenital dislocations of knees, hips, and elbows, and is often diagnosed initially as Larsen syndrome, humero-spinal dysostosis, or chondrodysplasia with dislocations. The incidence of CHST3 deficiency seems to be higher than assumed so far. The clinical and radiographic pattern (joint dislocations, vertebral changes, normal carpal age, lack of facial flattening, and recessive inheritance) is characteristic and distinguishes CHST3 deficiency from other disorders with congenital dislocations such as filamin B-associated dominant Larsen syndrome and Desbuquois syndrome.
我们最近报道了在六位被诊断为隐性 Larsen 综合征或肱骨脊柱发育不良的患者中碳水化合物磺基转移酶 3(CHST3;软骨素-6-磺基转移酶)的缺乏[Hermanns 等人(2008);美国人类遗传学杂志 82:1368-1374]。此后,我们发现了另外 17 个具有 CHST3 突变的家族,并在此报告了 23 个家族的 24 位患者。分子分析前的诊断假设是:Larsen 综合征(15 个家族)、肱骨脊柱发育不良(4 例)、多发性脱位性软骨发育不良(CDMD“Megarbane 型”;2 例)、Desbuquois 综合征(1 例)和脊椎-骨骺发育不良(1 例)。尽管诊断标签不同,但这些患者的临床特征相似,包括出生时膝关节和/或髋关节脱位、马蹄足、肘关节发育不良伴半脱位和伸展受限、身材矮小以及儿童后期进展性脊柱后凸。最有用的影像学线索是腰椎的变化。共发现 24 种不同的 CHST3 突变;16 名患者为纯合突变。我们得出结论,CHST3 缺乏症在出生时表现为膝关节、髋关节和肘关节先天性脱位,通常最初被诊断为 Larsen 综合征、肱骨脊柱发育不良或伴脱位的软骨发育不良。CHST3 缺乏症的发病率似乎比目前认为的要高。临床和影像学模式(关节脱位、椎体变化、正常腕骨年龄、无面部扁平、隐性遗传)具有特征性,可将 CHST3 缺乏症与其他伴先天性脱位的疾病(如显性 Filamin B 相关的 Larsen 综合征和 Desbuquois 综合征)区分开来。